Discrimination between NSIP- and IPF-Derived Fibroblasts Based on Multi-Parameter Characterization of Their Growth, Morphology and Physic-Chemical Properties.
ToF-SIMS
fibroblasts
force spectroscopy
idiopathic pulmonary fibrosis (IPF)
interstitial lung diseases (ILD)
nonspecific interstitial pneumonia (NSIP)
substrate elasticity
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
15 Feb 2022
15 Feb 2022
Historique:
received:
20
01
2022
revised:
10
02
2022
accepted:
14
02
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
19
3
2022
Statut:
epublish
Résumé
The aim of the research presented here was to find a set of parameters enabling discrimination between three types of fibroblasts, i.e., healthy ones and those derived from two disorders mimicking each other: idiopathic pulmonary fibrosis (IPF), and nonspecific interstitial pneumonia (NSIP). The morphology and growth of cells were traced using fluorescence microscopy and analyzed quantitatively using cell proliferation and substrate cytotoxicity indices. The viability of cells was recorded using MTS assays, and their stiffness was examined using atomic force microscopy (AFM) working in force spectroscopy (FS) mode. To enhance any possible difference in the examined parameters, experiments were performed with cells cultured on substrates of different elasticities. Moreover, the chemical composition of cells was determined using time-of-flight secondary ion mass spectrometry (ToF-SIMS), combined with sophisticated analytical tools, i.e., Multivariate Curve Resolution (MCR) and Principal Component Analysis (PCA). The obtained results demonstrate that discrimination between cell lines derived from healthy and diseased patients is possible based on the analysis of the growth of cells, as well as their physical and chemical properties. In turn, the comparative analysis of the cellular response to altered stiffness of the substrates enables the identification of each cell line, including distinguishing between IPF- and NSIP-derived fibroblasts.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of the research presented here was to find a set of parameters enabling discrimination between three types of fibroblasts, i.e., healthy ones and those derived from two disorders mimicking each other: idiopathic pulmonary fibrosis (IPF), and nonspecific interstitial pneumonia (NSIP).
METHODS
METHODS
The morphology and growth of cells were traced using fluorescence microscopy and analyzed quantitatively using cell proliferation and substrate cytotoxicity indices. The viability of cells was recorded using MTS assays, and their stiffness was examined using atomic force microscopy (AFM) working in force spectroscopy (FS) mode. To enhance any possible difference in the examined parameters, experiments were performed with cells cultured on substrates of different elasticities. Moreover, the chemical composition of cells was determined using time-of-flight secondary ion mass spectrometry (ToF-SIMS), combined with sophisticated analytical tools, i.e., Multivariate Curve Resolution (MCR) and Principal Component Analysis (PCA).
RESULTS
RESULTS
The obtained results demonstrate that discrimination between cell lines derived from healthy and diseased patients is possible based on the analysis of the growth of cells, as well as their physical and chemical properties. In turn, the comparative analysis of the cellular response to altered stiffness of the substrates enables the identification of each cell line, including distinguishing between IPF- and NSIP-derived fibroblasts.
Identifiants
pubmed: 35216278
pii: ijms23042162
doi: 10.3390/ijms23042162
pmc: PMC8880018
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Science Center
ID : UMO-2017/25/B/ST5/00575
Références
Chest. 2017 Oct;152(4):842-852
pubmed: 28400116
Int J Mol Sci. 2019 Apr 22;20(8):
pubmed: 31013581
Integr Biol (Camb). 2012 Apr;4(4):410-21
pubmed: 22410748
Am J Physiol Lung Cell Mol Physiol. 2018 Jul 1;315(1):L59-L65
pubmed: 29516782
Analyst. 2016 Oct 24;141(22):6217-6225
pubmed: 27704077
Am J Respir Crit Care Med. 2012 Nov 1;186(9):866-76
pubmed: 22936357
Biophys J. 2014 Aug 5;107(3):564-575
pubmed: 25099796
Am J Respir Cell Mol Biol. 2013 Apr;48(4):422-30
pubmed: 23258227
J Pathol. 2013 Jan;229(1):25-35
pubmed: 23018598
Biomed Microdevices. 2016 Oct;18(5):90
pubmed: 27620629
Front Med (Lausanne). 2021 Oct 18;8:744523
pubmed: 34733866
J Am Board Fam Med. 2018 Jan-Feb;31(1):151-162
pubmed: 29330249
Clin Chest Med. 2004 Sep;25(3):409-19, v
pubmed: 15331183
PLoS One. 2020 Jan 13;15(1):e0226084
pubmed: 31929532
PLoS One. 2015 Feb 18;10(2):e0117985
pubmed: 25692779
Chest. 2010 Jan;137(1):129-37
pubmed: 19749005
Diagnostics (Basel). 2021 Oct 22;11(11):
pubmed: 34829307
Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20;31(3):191-7
pubmed: 25363218
Micron. 2007;38(8):824-33
pubmed: 17709250
Thorax. 2007 Nov;62(11):1008-12
pubmed: 17965079
Eur Respir J. 2018 Aug 2;52(2):
pubmed: 29946005
Biointerphases. 2012 Dec;7(1-4):49
pubmed: 22893234
Anal Chem. 2015 Mar 17;87(6):3195-201
pubmed: 25688712
Antioxid Redox Signal. 2015 Jun 20;22(18):1646-66
pubmed: 25694038
Fibrogenesis Tissue Repair. 2014 Apr 29;7:7
pubmed: 24834127
Eur Respir J. 2011 Jun;37(6):1411-7
pubmed: 20884744
Bioinformatics. 2015 Mar 1;31(5):753-60
pubmed: 25452330
Respirology. 2016 Feb;21(2):259-68
pubmed: 26564810
Biochim Biophys Acta. 2008 Oct;1778(10):1947-77
pubmed: 18433715
Eur Respir Rev. 2017 Oct 3;26(145):
pubmed: 28974541
Eur Biophys J. 2012 Jan;41(1):79-87
pubmed: 22038077
BMJ Open Respir Res. 2020 Apr;7(1):
pubmed: 32265195
Can Respir J. 2020 Feb 25;2020:3406530
pubmed: 32184906
Eur J Radiol Open. 2020 Dec 16;8:100311
pubmed: 33364263
Am J Respir Crit Care Med. 2004 Oct 15;170(8):904-10
pubmed: 15256390
Chron Respir Dis. 2010 Aug;7(3):187-95
pubmed: 20688895
Biomech Model Mechanobiol. 2016 Jun;15(3):511-23
pubmed: 26206449
Langmuir. 2012 Jan 31;28(4):2131-6
pubmed: 22085048
J Mech Behav Biomed Mater. 2018 Dec;88:217-222
pubmed: 30193179
Am J Respir Crit Care Med. 2007 Oct 1;176(7):632-3
pubmed: 17881589
Pulm Pharmacol Ther. 2013 Aug;26(4):430-7
pubmed: 22706330
Am J Respir Crit Care Med. 2011 Feb 15;183(4):431-40
pubmed: 20935110
Sci Rep. 2017 Dec 5;7(1):16912
pubmed: 29208971
J Cell Biol. 2010 Aug 23;190(4):693-706
pubmed: 20733059
Ther Clin Risk Manag. 2019 Jan 03;15:73-81
pubmed: 30655671
Am J Respir Crit Care Med. 2007 May 15;175(10):1054-60
pubmed: 17255566
Respir Res. 2014 Dec 05;15:155
pubmed: 25476248
Physiol Rev. 2009 Jul;89(3):759-75
pubmed: 19584312
Sci Rep. 2020 Oct 28;10(1):18519
pubmed: 33116169
J Funct Biomater. 2014 May 08;5(2):43-57
pubmed: 24956439
PLoS One. 2014 Sep 12;9(9):e107055
pubmed: 25215577
Respir Res. 2021 May 4;22(1):135
pubmed: 33947414
Respir Res. 2015 Jul 01;16:82
pubmed: 26126411
Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1569-76
pubmed: 11029378
Mass Spectrom (Tokyo). 2013;2(Spec Iss):S0014
pubmed: 24349933
Sci Rep. 2020 Oct 5;10(1):16492
pubmed: 33020537
PLoS One. 2012;7(12):e51499
pubmed: 23240031
Physiol Rev. 2020 Apr 1;100(2):695-724
pubmed: 31751165
Biomed Res Int. 2013;2013:759760
pubmed: 24205507
Proc Am Thorac Soc. 2012 Jul;9(3):137-47
pubmed: 22802288
Pharmaceutics. 2020 Apr 24;12(4):
pubmed: 32344567
Am J Respir Crit Care Med. 2000 Dec;162(6):2259-64
pubmed: 11112149
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Front Bioeng Biotechnol. 2020 Dec 22;8:609653
pubmed: 33425874
Am J Respir Cell Mol Biol. 2001 May;24(5):591-8
pubmed: 11350829
Med Sci Monit. 2009 Jul;15(7):BR194-201
pubmed: 19564819
AJR Am J Roentgenol. 2005 Dec;185(6):1531-9
pubmed: 16304008
Int J Biochem Cell Biol. 2017 Feb;83:27-38
pubmed: 27974233
Soft Matter. 2018 Sep 19;14(36):7534-7541
pubmed: 30152838
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Respir Res. 2019 Sep 6;20(1):205
pubmed: 31492155
Am J Respir Crit Care Med. 2005 Aug 1;172(3):268-79
pubmed: 15879420
Biophys J. 2007 Dec 15;93(12):4453-61
pubmed: 18045965
Am Rev Respir Dis. 1987 Oct;136(4):1066
pubmed: 3662229
Eur Respir J. 2010 Mar;35(3):496-504
pubmed: 20190329
Mol Biol Cell. 2017 Dec 15;28(26):3741-3755
pubmed: 29046395
Med Sci (Basel). 2018 Sep 04;6(3):
pubmed: 30181506
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
Langmuir. 2004 Dec 21;20(26):11684-91
pubmed: 15595798
Micron. 2020 Dec;139:102948
pubmed: 33065514
Thorax. 2007 May;62(5):428-37
pubmed: 17251318
Am J Respir Crit Care Med. 2002 Jun 15;165(12):1654-69
pubmed: 12070068
Radiology. 2017 Jul;284(1):255-263
pubmed: 28182861
PLoS One. 2015 Feb 13;10(2):e0116840
pubmed: 25679502
Am J Respir Cell Mol Biol. 2020 Feb;62(2):191-203
pubmed: 31486669
Am J Respir Crit Care Med. 2008 Jun 15;177(12):1338-47
pubmed: 18388353
J Mech Behav Biomed Mater. 2015 Jan;41:13-22
pubmed: 25460399
Diagnostics (Basel). 2021 Apr 23;11(5):
pubmed: 33922858
Front Med (Lausanne). 2019 Oct 31;6:246
pubmed: 31750308
South Med J. 2017 Jun;110(6):393-398
pubmed: 28575896
Med Sci (Basel). 2018 Nov 29;6(4):
pubmed: 30501130